Rigel Pharmaceuticals, Inc.RIGLNASDAQ
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank51
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P51
Within normal range
vs 5Y Ago
-0.4x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | -8.53% |
| Q3 2025 | -21.31% |
| Q2 2025 | 3519.60% |
| Q1 2025 | -106.16% |
| Q4 2024 | -33.10% |
| Q3 2024 | 7078.48% |
| Q2 2024 | 106.02% |
| Q1 2024 | 19.66% |
| Q4 2023 | -359.16% |
| Q3 2023 | -122.92% |
| Q2 2023 | 245.56% |
| Q1 2023 | 81.40% |
| Q4 2022 | -64.72% |
| Q3 2022 | -3.02% |
| Q2 2022 | 49.64% |
| Q1 2022 | -34.32% |
| Q4 2021 | -85.35% |
| Q3 2021 | -118.65% |
| Q2 2021 | 376.70% |
| Q1 2021 | -28.15% |
| Q4 2020 | 20.07% |
| Q3 2020 | -38.78% |
| Q2 2020 | -353.86% |
| Q1 2020 | 67.94% |
| Q4 2019 | 34.10% |
| Q3 2019 | 12.07% |
| Q2 2019 | -2826.36% |
| Q1 2019 | -104.89% |
| Q4 2018 | 157.98% |
| Q3 2018 | 25.61% |
| Q2 2018 | -15.39% |
| Q1 2018 | -18.66% |
| Q4 2017 | -11.95% |
| Q3 2017 | 9.55% |
| Q2 2017 | 6.22% |
| Q1 2017 | -66.58% |
| Q4 2016 | 44.78% |
| Q3 2016 | -22.44% |
| Q2 2016 | 17.78% |
| Q1 2016 | -62.50% |